IGM Biosciences, Inc.
igmbio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2025 10-Q, filed Jul 31, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Nov 13, 2025.
10-Q for Q2 FY2025, filed Jul 31, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops engineered IgM antibodies for autoimmune and inflammatory diseases, with research and development for immunology targets under a collaboration with Sanofi.
10-K for FY2024, filed Mar 6, 2025We are a biotechnology company that has historically been focused on the development of IgM antibodies for the treatment of cancer and…View ↗
We have created a portfolio of patents and patent applications, know-how and trade secrets directed to our platform technology and we…View ↗
Following the 2025 Restructuring, our only ongoing IgM-related efforts relate to the targets we are developing under the Sanofi Agreement…View ↗
Who Were Their Customers?
Sanofi is the collaboration partner for IgM antibody research and development on immunology targets.
10-K for FY2024, filed Mar 6, 2025We have created a portfolio of patents and patent applications, know-how and trade secrets directed to our platform technology and we…View ↗
In March 2022, we entered into a global collaboration and license agreement with Genzyme Corporation (Sanofi Agreement), a wholly owned…View ↗
For each immunology Collaboration Target program, we will be responsible for conducting research and development activities through the…View ↗
Did Revenues Turn Into Profits?
No. It lost $195.8M in .
10-K for FY2024, filed Mar 6, 2025
−$208.6MView ↗
10-K for FY2024, filed Mar 6, 2025
−$195.8MView ↗
10-K for FY2024, filed Mar 6, 2025
−$158.8MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2025, filed Jul 31, 2025
$97.6MView ↗
- ▲ Now profitable
- vs −$47.9M in Q2 FY2024
-
Aug 14, 2025
Concentra completed its acquisition of IGM Biosciences.
Shares were exchanged for cash and a contingent value right, and IGM became a wholly owned subsidiary of Concentra.
Sources
8-K, filed Aug 14, 2025
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on August 14, 2025, Parent completed a tender…View ↗
-
Jul 1, 2025
IGM agreed to be acquired by Concentra.
The agreement provided for a cash tender offer plus a contingent value right for each share, followed by a merger.
Sources
8-K, filed Jul 1, 2025
On July 1, 2025, IGM Biosciences, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Concentra…View ↗
-
May 8, 2025
Sanofi terminated its collaboration and license agreement.
IGM said it cut its remaining workforce by approximately 80% and closed most remaining lab and office facilities.
Sources
8-K, filed May 8, 2025
In connection with the Agreement termination, the Company implemented an approximately 80% reduction in its remaining workforce and closed…View ↗
A narrower disease focus
The older report described IgM antibody development for cancer, infectious diseases, and autoimmune and inflammatory diseases; the latest report describes a focus on autoimmune disease and continuing immunology work under the Sanofi agreement.
10-K for FY2021, filed Mar 29, 2022 10-K for FY2024, filed Mar 6, 2025In September 2024, we announced a strategic pivot to focus exclusively on autoimmunity. We also announced an extension of our cash runway…View ↗
Following the 2025 Restructuring, our only ongoing IgM-related efforts relate to the targets we are developing under the Sanofi Agreement…View ↗
In April 2024, Sanofi exercised its right to terminate the oncology collaboration targets effective June 2024. As a result of this…View ↗
Clinical programs paused
The older report listed product candidates in clinical testing, while the latest report says there are no ongoing clinical trials and that ongoing IgM efforts are limited to Sanofi targets.
10-K for FY2021, filed Mar 29, 2022 10-K for FY2024, filed Mar 6, 2025IGM-2323: A bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins currently in a Phase 2 clinical trial for the treatment…View ↗
IGM-8444: An IgM antibody targeting Death Receptor 5 (DR5) proteins, which may prove to be useful for the treatment of patients with solid…View ↗
Our oncology pipeline also includes IGM-7354, an anti-PD-L1 IgM antibody that targets the delivery of interleukin-15 (IL-15) cytokines to…View ↗
Following the 2025 Restructuring, our only ongoing IgM-related efforts relate to the targets we are developing under the Sanofi Agreement…View ↗
Who Did They Compete With?
Competes with AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson and Johnson, Novartis, Pfizer, and Takeda
10-K for FY2024, filed Mar 6, 2025We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop therapies for autoimmune disease.…View ↗
Loading...
